Enanta Pharmaceuticals, Inc.
ENTANASDAQHealthcare● Active
$10.93
$-0.36(-3.15%)
Market Cap$253641759
P/E Ratio—
52W High$17.15
52W Low$6.435
Enanta Pharmaceuticals, Inc. (ENTA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ENTA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.45
Est. -$0.46 · +2.2%
Revenue
$0.02B
Est. $0.02B · +0.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS🔥 4-Quarter EPS Beat Streak
ENTA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.45 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$0.46 | -$0.45 | +2.2% | $0.02B | $0.02B | +0.8% |
| ▲ Q1 FY2026 | Feb 9, 2026 | -$0.54 | -$0.42 | +22.2% | $0.02B | $0.02B | +17.0% |
| ▲ Q4 FY2025 | Nov 17, 2025 | -$1.13 | -$0.87 | +23.0% | $0.02B | $0.02B | -5.3% |
| ▲ Q3 FY2025 | Aug 11, 2025 | -$1.25 | -$0.85 | +32.0% | $0.02B | $0.02B | +14.7% |
| ▼ Q2 FY2025 | May 12, 2025 | -$1.04 | -$1.06 | -1.9% | $0.01B | $0.02B | -6.5% |
| ▲ Q1 FY2025 | Feb 10, 2025 | -$1.16 | -$1.05 | +9.5% | $0.02B | $0.02B | -1.7% |
| ▼ Q4 FY2024 | Nov 25, 2024 | -$1.16 | -$1.36 | -17.2% | $0.07B | $0.02B | +277.2% |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.45
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.45
EPS Est.
-$0.46
EPS Surpr.
+2.2%
Revenue
$0.02B
Q1 FY2026
Feb 9, 2026Beat
EPS Actual
-$0.42
EPS Est.
-$0.54
EPS Surpr.
+22.2%
Revenue
$0.02B
Q4 FY2025
Nov 17, 2025Beat
EPS Actual
-$0.87
EPS Est.
-$1.13
EPS Surpr.
+23.0%
Revenue
$0.02B
Q3 FY2025
Aug 11, 2025Beat
EPS Actual
-$0.85
EPS Est.
-$1.25
EPS Surpr.
+32.0%
Revenue
$0.02B
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$1.06
EPS Est.
-$1.04
EPS Surpr.
-1.9%
Revenue
$0.01B
Q1 FY2025
Feb 10, 2025Beat
EPS Actual
-$1.05
EPS Est.
-$1.16
EPS Surpr.
+9.5%
Revenue
$0.02B
Q4 FY2024
Nov 25, 2024Miss
EPS Actual
-$1.36
EPS Est.
-$1.16
EPS Surpr.
-17.2%
Revenue
$0.07B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $-0.57 | $-0.49 | $-0.40 | 1 |
| Q2 FY2027 | $-0.51 | $-0.43 | $-0.36 | 1 |
| Q1 FY2027 | $-0.50 | $-0.43 | $-0.35 | 1 |
| Q4 FY2026 | $-0.42 | $-0.36 | $-0.30 | 1 |
| Q3 FY2026 | $-0.90 | $-0.62 | $-0.34 | 3 |
| Q2 FY2026 | $-0.62 | $-0.45 | $-0.27 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +2.2% | $15.34 | $15.46 | +0.78% |
| ▲ Q1 FY2026 | Feb 9, 2026 | +22.2% | $13.51 | $13.83 | +2.37% |
| ▲ Q4 FY2025 | Nov 17, 2025 | +23.0% | $12.06 | $12.82 | +6.30% |
| ▲ Q3 FY2025 | Aug 11, 2025 | +32.0% | $6.90 | $6.49 | -5.94% |
| ▼ Q2 FY2025 | May 12, 2025 | -1.9% | $5.27 | $5.55 | +5.31% |
| ▲ Q1 FY2025 | Feb 10, 2025 | +9.5% | $4.90 | $4.90 | +0.00% |
| ▼ Q4 FY2024 | Nov 25, 2024 | -17.2% | $9.34 | $9.01 | -3.53% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +28.2% | $13.90 | $12.85 | -7.55% |
Q2 FY2026+0.78%
Report Date
May 11, 2026
EPS Beat/Miss
+2.2%
Price Before
$15.34
Price After
$15.46
Q1 FY2026+2.37%
Report Date
Feb 9, 2026
EPS Beat/Miss
+22.2%
Price Before
$13.51
Price After
$13.83
Q4 FY2025+6.30%
Report Date
Nov 17, 2025
EPS Beat/Miss
+23.0%
Price Before
$12.06
Price After
$12.82
Q3 FY2025-5.94%
Report Date
Aug 11, 2025
EPS Beat/Miss
+32.0%
Price Before
$6.90
Price After
$6.49
Q2 FY2025+5.31%
Report Date
May 12, 2025
EPS Beat/Miss
-1.9%
Price Before
$5.27
Price After
$5.55
Q1 FY2025+0.00%
Report Date
Feb 10, 2025
EPS Beat/Miss
+9.5%
Price Before
$4.90
Price After
$4.90
Q4 FY2024-3.53%
Report Date
Nov 25, 2024
EPS Beat/Miss
-17.2%
Price Before
$9.34
Price After
$9.01
Q3 FY2024-7.55%
Report Date
Aug 5, 2024
EPS Beat/Miss
+28.2%
Price Before
$13.90
Price After
$12.85
Avg Beat Reaction-0.67%
Avg Miss Reaction+0.89%
Beat Rate6 / 8 quarters
Largest Move-7.55% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ENTA ends December
Enanta Pharmaceuticals, Inc. (ENTA) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.45 — beating the analyst consensus of $-0.46 by +2.2%. ENTA has beaten EPS estimates for 4 consecutive quarters. The next ENTA earnings date is expected around September 1, 2026.
Each quarter, investors track ENTA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ENTA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ENTA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ENTA earnings · 5 questionsEnanta Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ENTA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ENTA historically reports after market close (AMC).
ENTA earnings datewhen is ENTA earningsENTA next earnings datewhen does ENTA report earningsENTA earnings calendar
▸ Source: FMP · Enanta Pharmaceuticals, Inc. SEC filings · US GAAP · Enanta Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026